The Insight Partners Latest Research for Report “Antibiotics Market Forecast to 2028″ Focuses COVID-19 Impact and Global Analysis By Drug Class (Sulfonamides, Aminoglycosides, Carbapenem, Macrolides, Fluoroquinolones, Penicillin, Cephalosporin, Others); Action Mechanism (Mycolic Acid Inhibitors, RNA Synthesis Inhibitors, DNA Synthesis Inhibitors, Protein Synthesis Inhibitors, Cell Wall Synthesis Inhibitors) and Geography
Antibiotics Market Forecast to 2028 – Covid-19 Impact and Global Analysis by Drug Class and Action Mechanism.’ The global antibiotics market was valued at US$ 44,111.31 million in 2020 and is projected to reach US$ 59,253.24 million by 2028; it is expected to grow at a CAGR of 4.0% during 2021–2028. The report provides trends prevailing in the global antibiotics market and the factors driving market along with those that act as hindrances.
Download PDF Sample Copy at:
Antibiotics are powerful medicines that are used to fight against bacterial infections. Antibiotics are also known as antibacterial which include a range of powerful drugs and are used to treat diseases caused by bacteria.
Industry Players Analysis:
Market leaders operating in the market have undertaken various organic growth strategies in the antibiotics Market. The antibiotics market majorly consists of the players such as Sanofi., Novartis AG., Pfizer Inc, Bayer AG, Johnson & Johnson Services, Inc, Bristol-Myers Squibb Company, Astellas Pharma Inc , Abbott, Eli Lilly and Company among others. Several organic approaches, such as product launches, and expansion/relocation in the antibiotics Market, have resulted in the positive growth of the market. Product launches help the company to strengthen its product offering and the customer base, which allows the company to hold a strong position in the market. Similarly, utilizing expansion activities, it is easy to venture into untapped economies and use the opportunities being offered.
Below is the list of the growth strategies done by the players operating in the Antibiotics market:
Dec-2016: Pfizer Inc. announced that it has completed the acquisition of the development and commercialization rights to AstraZeneca’s late-stage small molecule anti-infective business, primarily outside the United States. The agreement includes the commercialization and development rights to the newly approved EU drug Zavicefta (ceftazidime-avibactam), the marketed agents Merrem/Meronem (meropenem) and Zinforo (ceftaroline fosamil), and the clinical development assets aztreonam-avibactam (ATM-AVI) and CXL
May-2017: Pfizer’s lauched new antibiotic for multidrug resistant (MDR) infections – Zavicefta – in the UK and Germany, its first EU markets
Have a Call with Analyst:
September-2019: Astellas Pharma Inc.Announces Launch of Dafclir Tablets for the Treatment of Infectious Enteritis Caused by Clostridium difficile in Japan. It is likely to increase the action of selective antibacterial spectrum
Based on action mechanism, the antibiotics market has been segmented into cell wall synthesis inhibitors, protein synthesis inhibitors, DNA synthesis inhibitors, RNA synthesis inhibitors, mycolic acid inhibitors, and others. The cell wall synthesis inhibitors segment held the largest share of the market in 2020; whereas the DNA synthesis inhibitors segment is estimated to register the highest CAGR of 5.2% in the market during the forecast period. Such growing prevalence of infectious disease in different regions across the world is raising the global demand for the antibiotics.
Based on n drug class, the antibiotics market is segmented into Cephalosporin, Penicillin, Fluoroquinolones, Macrolides, Carbapenem, Aminoglycosides, Sulfonamides, and Others. The cephalosporin segment held the largest share of the market in 2020; however the fluoroquinolones segment is anticipated to register the highest CAGR of 5.3% in the market during the forecast period. Additionally, increasing incidence of pneumonia, bloodstream infections, and Urinary Tract Infections (UTI) is expected to increase the demand for carbapenems class of antibiotics in coming years. Moreover, the lower price of generic carbapenem-based antibiotics is expected to result in increased product adoption, thus compelling carbapenem-based antibiotic manufacturers to develop geographical footprint in lower and middle-income countries.
Buy Report at:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi